Gene Therapy in Retinal Dystrophies
Open accessThe DOI matches its Crossref record; 187 of the 188 references it cites were found in a registry or an index.
Abstract
Inherited retinal dystrophies (IRDs) are a group of clinically and genetically heterogeneous degenerative disorders. To date, mutations have been associated with IRDs in over 270 disease genes, but molecular diagnosis still remains elusive in about a third of cases. The methodologic developments in genome sequencing techniques that we have witnessed in this last decade have represented a turning point not only in diagnosis and prognosis but, above all, in the identification of new therapeutic perspectives. The discovery of new disease genes and pathogenetic mechanisms underlying IRDs has laid the groundwork for gene therapy approaches. Several clinical trials are ongoing, and the recent approval of Luxturna, the first gene therapy product for Leber congenital amaurosis, marks the beginning of a new era. Due to its anatomical and functional characteristics, the retina is the organ of choice for gene therapy, although there are quite a few difficulties in the translational approaches from preclinical models to humans. In the first part of this review, an overview of the current knowledge on methodological issues and future perspectives of gene therapy applied to IRDs is discussed; in the second part, the state of the art of clinical trials on the gene therapy approach in IRDs is illustrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
RNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · cited 12×
“The limit of HDR is that it occurs much less frequently than NHEJ in the S and G2 phases of cell division.”
InfluentialSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundKetting, R. F., Fischer, S. E. J., Bernstein, E., Sijen, T., Hannon, G. J., & Plasterk, R. H. A. (2001) · Genes & Development · doi:10.1101/gad.927801 · Cited by 1,852
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 1
- Tsang S.H. Gouras P. Molecular physiology and pathology of the retina Duane’s Clinical Opthalmology Duane T.D. Tasman W. Jaeger A.E. Lippincott-Raven Philadelphia, PA, USA 1996
Cited by
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Maya-Vetencourt, J. F., Manfredi, G., Mete, M., Colombo, E., Bramini, M., Di Marco, S., Shmal, D., Mantero, G., Dipalo, M., Rocchi, A., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0696-3 · Cited by 211
Barani, M., Nematollahi, M. H., Zaboli, M., Mirzaei, M., Torkzadeh‐Mahani, M., Pardakhty, A., & Asadikaram, G. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.09.026 · Cited by 98
The Role of Inflammation in Retinal Neurodegeneration and Degenerative Diseases
Kaur, G., & Singh, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010386 · Cited by 101
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
BackgroundChhabra, A., Bashirians, G., Petropoulos, C. J., Wrin, T., Paliwal, Y., Henstock, P. V., Somanathan, S., Pereira, C. D. F., Winburn, I. C., & Rasko, J. E. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101273 · Cited by 92
Colombo, L., Maltese, P. E., Castori, M., Shamieh, S. E., Zeitz, C., Audo, I. S., Zulian, A., Marinelli, C., Benedetti, S., Costantini, A., et al. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.2.13 · Cited by 77
Ionic Liquids for Enhanced Drug Delivery: Recent Progress and Prevailing Challenges
Liu, C., Chen, B., Shi, W., Huang, W., & Qian, H. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00960 · Cited by 75
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
Leroy, B. P., Birch, D. G., Duncan, J. L., Lam, B. L., Koenekoop, R. K., Porto, F. B. O., Russell, S. R., & Girach, A. (2021) · Retina · doi:10.1097/iae.0000000000003133 · Cited by 71
How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?
Sainz-Ramos, M., Gallego, I., Villate-Beitia, I., Sesma, J. Z., Maldonado, I., Puras, G., & Pedraz, J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147545 · Cited by 76
Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes
Adachi, H., Pan, Y., He, X., Chen, J. L., Klein, B., Platenburg, G. J., Morais, P., Boutz, P. L., & Yu, Y. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.009 · Cited by 70
The Role of Rac GTPase in Dendritic Spine Morphogenesis and Memory
Costa, J. F., Dines, M., & Lamprecht, R. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00012 · Cited by 66
Tanaka, H., Sakurai, Y., Anindita, J., & Akita, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.001 · Cited by 56
Succinic Semialdehyde Dehydrogenase Deficiency: An Update
Didiasova, M., Banning, A., Brennenstuhl, H., Jung-Klawitter, S., Cinquemani, C., Opladen, T., & Tikkanen, R. (2020) · Cells · doi:10.3390/cells9020477 · Cited by 52
Yuan, B., Aziz, M. R. F., Li, S., Wu, J., Li, D., & Li, R. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.036 · Cited by 51
Sallum, J. M. F., Kaur, V. P., Shaikh, J., Banhazi, J., Spera, C., Aouadj, C., Viriato, D., & Fischer, M. D. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02036-7 · Cited by 49
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy
Kang, C., & Scott, L. J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00475-6 · Cited by 43
RNA-based therapies in inherited retinal diseases
Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., et al. (2022) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414221134602 · Cited by 36
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
Numa, S., Oishi, A., Higasa, K., Oishi, M., Miyata, M., Hasegawa, T., Ikeda, H. O., Otsuka, Y., Matsuda, F., & Tsujikawa, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77558-1 · Cited by 37
Targeting of the NRL Pathway as a Therapeutic Strategy to Treat Retinitis Pigmentosa
Moore, S. M., Skowronska‐Krawczyk, D., & Chao, D. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072224 · Cited by 31
New pharmacotherapy options for noninfectious posterior uveitis
Pleyer, U., Neri, P., & Deuter, C. (2021) · International Ophthalmology · doi:10.1007/s10792-021-01763-8 · Cited by 33
Lacy, G. D., Abalem, M. F., Andrews, C., Abuzaitoun, R., Popova, L., Santos, E. P., Yu, G., Rakine, H. Y., Baig, N., Ehrlich, J. R., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.12.001 · Cited by 30
Balzamino, B. O., Cacciamani, A., Dinice, L., Cecere, M., Pesci, F. R., Ripandelli, G., & Micera, A. (2024) · Biology · doi:10.3390/biology13121030 · Cited by 37
CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases
Rasoulinejad, S. A., & Maroufi, F. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00345-4 · Cited by 26
Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy
Battu, R., Ratra, D., & Gopal, L. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_82_22 · Cited by 26
Key considerations in formulation development for gene therapy products
Mohammad, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.013 · Cited by 24
Challenges in molecular diagnosis of X-linked Intellectual disability
Luca, C. D., Race, V., Keldermans, L., Bauters, M., & Esch, H. V. (2019) · British Medical Bulletin · doi:10.1093/bmb/ldz039 · Cited by 29
Liu, X., Pacwa, A., Bresciani, G., Swierczynska, M., Dorecka, M., & Smędowski, A. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00875-y · Cited by 27
Understanding the genetic architecture of human retinal degenerations
Hejtmancik, J. F., & Daiger, S. P. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922925117 · Cited by 21
Poboży, K., Poboży, T., Domański, P., Derczyński, M., Konarski, W., & Domańska-Poboża, J. (2025) · Biomedicines · doi:10.3390/biomedicines13020429 · Cited by 20
Exploring the Role of Gene Therapy for Neurological Disorders
Puranik, N., Yadav, D., Chauhan, P., Kwak, M., & Jin, J. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200917114101 · Cited by 20
Wang, Y., Punzo, C., Ash, J. D., & Lobanova, E. S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2118479119 · Cited by 18
Brophy, M. L., Stansfield, J. C., Ahn, Y., Cheng, S. H., Murphy, J. E., & Bell, R. D. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12468 · Cited by 18
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 19
Simonelli, F., Sodi, A., Falsini, B., Bacci, G. M., Iarossi, G., Iorio, V. D., Giorgio, D., Placidi, G., Andrao, A., Reale, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061080 · Cited by 17
Retinal Degeneration: Molecular Mechanisms and Therapeutic Strategies
Wu, X., Yan, N., & Zhang, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211129122908 · Cited by 16
Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa
Kwak, J. J., Kim, H. R., & Byeon, S. H. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.7.701 · Cited by 16
Pasquini, G., Cora, V., Swiersy, A., Achberger, K., Antkowiak, L., Müller, B., Wimmer, T., Fraschka, S. A. K., Casadei, N., Ueffing, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041380 · Cited by 16
Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review
Jain, R., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.69895 · Cited by 24
Simonelli, F., Sodi, A., Falsini, B., Bacci, G. M., Iarossi, G., Iorio, V. D., Giorgio, D., Placidi, G., Andrao, A., Reale, L., et al. (2021) · Clinical ophthalmology · doi:10.2147/opth.s331218 · Cited by 13
Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis
Li, B., Tan, W., Wang, Z., Zhou, H., Zou, J., Li, Y., Yoshida, S., & Zhou, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18228 · Cited by 14
Molecular genetics of inherited retinal degenerations in Icelandic patients
Thorsteinsson, D. A., Stefánsdóttir, V., Eysteinsson, Þ., Thórisdóttir, S., & Jónsson, J. J. (2021) · Clinical Genetics · doi:10.1111/cge.13967 · Cited by 13
Velez, G., & Mahajan, V. B. (2020) · iScience · doi:10.1016/j.isci.2020.101667 · Cited by 13
Najafi, S., Rahimpour, A., Ahmadieh, H., Tehrani, M. M., Khalilzad, M. A., Suri, F., & Ranjbari, J. (2024) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2024.07.005 · Cited by 11
Ocular manifestations of renal ciliopathies
Salehi, O., Mack, H. G., Colville, D. J., Lewis, D. A., & Savige, J. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06096-5 · Cited by 14
Current state of developing advanced therapies for rare diseases in the European Union
Qiu, T., Wang, Y., Dabbous, M., Hanna, E., Han, R., Liang, S., & Toumi, M. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1835640 · Cited by 11
Sauter, M. M., Noel, H. R., Sinha, D., Nelson, E. C., Xiong, M. N., Gamm, D. M., & Brandt, C. R. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110478 · Cited by 10
Unlocking ocular therapy: Harnessing the power of non-coding RNAs
Mohammadzadeh, V., Mostajeran, N., Shaban, M., Atapour‐Mashhad, H., Rad, B. T., Feizpour, R., Ghazy, E., Rahdar, A., & Fathi‐karkan, S. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105847 · Cited by 10
Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration
Khan, I., Ramzan, F., Tayyab, H., & Damji, K. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094078 · Cited by 10
Strategies to Improve the Targeting of Retinal Cells by Non-Viral Gene Therapy Vectors
Bitoque, D. B., Fernandes, C. F., Oliveira, A. M. L., & Silva, G. A. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.899260 · Cited by 9
Matsevich, C., Gopalakrishnan, P., Chang, N., Obolensky, A., Beryozkin, A., Salameh, M., Kostic, C., Sharon, D., Arsenijévic, Y., & Banin, E. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.011 · Cited by 10
Palfi, A., Yesmambetov, A., Millington‐Ward, S., Shortall, C., Humphries, P., Kenna, P. F., Chadderton, N., & Farrar, G. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00891 · Cited by 9
Altay, H. Y., Özdemir, F., Afghah, F., Kilinç, Z., Ahmadian, M., Tschopp, M., & Ağca, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.924917 · Cited by 12
Lisbjerg, K., Bertelsen, M., Forman, J. L., Grønskov, K., Holtan, J. P., & Kessel, L. (2022) · Ophthalmic Genetics · doi:10.1080/13816810.2022.2123006 · Cited by 8
Areblom, M., Kjellström, S., Andréasson, S., Öhberg, A., Gränse, L., & Kjellström, U. (2023) · Genes · doi:10.3390/genes14071413 · Cited by 8
AMD and Stem Cell-Based Therapies
Giacalone, J. C., Parkinson, D. H., Balikov, D. A., & Rao, R. C. (2023) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000510 · Cited by 7
Fujinami, K., Akiyama, K., Tsunoda, K., Ito, S., Seko, N., & Yamamoto, S. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100876 · Cited by 7
Ziraldo, G., Cupini, S., Sesti, V., Delfino, E., Lanzani, G., Bertarelli, C., Benfenati, F., & Marco, S. D. (2025) · Nature Communications · doi:10.1038/s41467-025-55882-2 · Cited by 10
Minnaert, A., Devoldere, J., Peynshaert, K., Vercruysse, L., Smedt, S. C. D., & Remaut, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010074 · Cited by 6
Marques, J. P., Soares, C. A., Carvalho, A. L., Estrela‐Silva, S., Santos, L. C., Ramos, L. M., & Silva, E. G. D. (2025) · Clinical Genetics · doi:10.1111/cge.14691 · Cited by 5
Paez-Escamilla, M. A., Alabek, M. L., Beale, O., Prensky, C. J., Lejoyeux, R., Friberg, T. R., Sahel, J., & Rosin, B. (2023) · Diagnostics · doi:10.3390/diagnostics13233521 · Cited by 5
Sauter, M. M., & Brandt, C. R. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108436 · Cited by 5
Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
Gemayel, M. C., Byrne, L. C., Ciulla, T. A., & Sahel, J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000360 · Cited by 5
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
Challenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
Relative frequency of inherited retinal disorders in Khuzestan province, southern Iran
Feghhi, M., Moghimi, M. A., Kasiri, A., & Farrahi, F. (2023) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/eu0ov98ooe · Cited by 3
Multimodal analysis in symptomatic MIDD-associated retinopathy. A case report and literature review
Chwiejczak, K., Byles, D. B., Gerry, P., Lany, H. V., Tasiopoulou, A., & Hattersley, A. T. (2023) · PubMed Central · doi:10.3205/oc000231 · Cited by 3
Phenotype and genotype of 15 Saudi patients with achromatopsia: A case series
Danish, E., Alhashem, A. M., AlJehani, R., Aljawi, A., Aldarwish, M., Mutairi, F. A., Alfadhel, M., Alrifai, M. T., & Alobaisi, S. (2023) · Saudi Journal of Ophthalmology · doi:10.4103/sjopt.sjopt_108_23 · Cited by 4
Let-7, Lin28 and Hmga2 Expression in Ciliary Epithelium and Retinal Progenitor Cells
Frasson, L. T., Dalmaso, B., Akamine, P. S., Kimura, E. T., Hamassaki‐Britto, D. E., & Debbio, C. B. D. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.3.31 · Cited by 3
Xu, Z., Liang, Y., Zhang, S., Liu, Y., Liu, S., Liang, S., Li, Z., Guan, T., Xu, Y. H., & Zeng, H. (2025) · Visual Neuroscience · doi:10.48130/vns-0025-0003 · Cited by 2
Exploring the Genetic Causes of Nonsyndromic Retinal Dystrophies in Qatar
Abiib, S., Khodjet‐El‐Khil, H., Bux, R. I., El‐Akouri, K., Okashah, S., Omran, T. B., Saleh, R. A., & Al-Shafai, M. N. (2025) · Genes · doi:10.3390/genes16121415 · Cited by 2
Ophthalmic Drug Discovery in the United States over the past Two Decades
Gu, D., & Janetos, T. M. (2020) · Ophthalmic Epidemiology · doi:10.1080/09286586.2020.1786591 · Cited by 3
A Scoping Review of Patient and Public Perspectives on Cell and Gene Therapies
Macpherson, K., Aiyegbusi, O. L., Elston, L., Myles, S., Washington, J., Sungum, N., Briggs, M., Newsome, P. N., & Calvert, M. (2021) · Regenerative Medicine · doi:10.2217/rme-2020-0181 · Cited by 2
Neutral Nanocomplex Delivers Plasmid Encoding α‐Hemolysin for Uveal Melanoma Treatment
Wu, S., He, L., Yang, L., Li, X., Wang, J., Ren, M., Gao, Y., Chen, Y., Wei, H., Zhang, M., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400187 · Cited by 2
Cloud-based genomics pipelines for ophthalmology: reviewed from research to clinical practice
Wong, D., Olivera, M., Yu, J., Szabó, A., Moghul, I., Balaskas, K., Luben, R., Khawaja, A. P., Pontikos, N., & Keane, P. A. (2021) · Modeling and Artificial Intelligence in Ophthalmology · doi:10.35119/maio.v3i1.115 · Cited by 2
Stem Cell and Gene Therapy for Inherited Retinal Diseases
DeSouza, P. J., Park, U. C., & Park, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_3 · Cited by 2
AAV-mediated generation of neurons in injury-induced and inherited retinal degenerationsPreprint
Yang, M.-L., Awad, S., Chung, A., Dang, J., Chong, M., Flickinger, Z., Wong, K. Y., & Hoang, T. V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.28.688728 · Cited by 2
Crawford, D. K., Vanlandingham, P. A., Schneider, S. M., & Goddeeris, M. M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108274 · Cited by 1
Evaluation of maximal dosing volume for intravitreal injections in cynomolgus monkeys
Sakata, M., Araki, T., & Tomohiro, M. (2023) · Fundamental Toxicological Sciences · doi:10.2131/fts.10.157 · Cited by 1
Colombo, L., Bonetti, G., Maltese, P. E., Iarossi, G., Ziccardi, L., Fogagnolo, P., RUVO, V. D., Murro, V., Giorgio, D., Falsini, B., et al. (2024) · Ophthalmic Research · doi:10.1159/000538746 · Cited by 6
Self-citationAAV-mediated transduction of songbird retina
Seth, P. K., Heyers, D., Satish, B., Mendoza, E., Haase, K., Borowsky, L., Musielak, I., Koch, K., Feederle, R., Scharff, C., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1549585 · Cited by 1
Exploring the potential for gene therapy in Cav1.4-related retinal channelopathies
Ganglberger, M., & Koschak, A. (2025) · Channels · doi:10.1080/19336950.2025.2480089 · Cited by 1
Bhat, M. A., & Goyal, S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10927-3 · Cited by 1
Chuchmacz, W., Bobowska, B., Forma, A., Dzierżyński, E., Puźniak, D., Teresińska, B., Baj, J., & Dolar-Szczasny, J. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120605 · Cited by 1
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
New era of personalized medicine: Advanced therapy medicinal products in Europe
García-González, J., Marhuenda-Castillo, S., Romero-Carretero, S., & Beltrán-García, J. (2021) · World Journal of Immunology · doi:10.5411/wji.v11.i1.1 · Cited by 3
Endpoints for Measuring Efficacy in Clinical Trials for Inherited Retinal Disease
Chung, D. C., Birch, D. G., & MacLaren, R. E. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000388 · Cited by 1
Gene therapies for retinal dystrophies: potential in the Chinese population
Kwok, A. K. H., & Wong, H. L. (2022) · Hong Kong Journal of Ophthalmology · doi:10.12809/hkjo-v26n1-324 · Cited by 1
Gage, H., Wetherill, L. F., Anderson, K., Conboy, E. E., & Haider, K. M. (2023) · Ophthalmic Genetics · doi:10.1080/13816810.2023.2209170 · Cited by 1
Ciccioli, M., & Antacle, A. (2024) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v17.n01.284 · Cited by 2
Sechrest, E. R. (2021) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.8099
Targeted Pseudouridylation: A Novel Approach for Suppressing Nonsense Mutations in Disease GenesPreprint
Adachi, H., Chen, J., Klein, B., Platenburg, G. J., Morais, P., & Yu, Y. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988395 · Cited by 1
(2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835af8de
(2022) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.21048
Involvement of the Purinergic System in Cell Death in Models of Retinopathies
Cruz, D. P., Repossi, M. G., & Madeira, L. F. (2022) · Biochemistry · doi:10.5772/intechopen.103935
Sakata, M., Araki, T., & Tomohiro, M. (2023) · Fundamental Toxicological Sciences · doi:10.2131/fts.10.199
TINKLAINĖS DISTROFIJOS GENŲ TERAPIJOS GALIMYBĖS IR PERSPEKTYVA
Kobeckis, K. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.001
Metadata
- Authors
- Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M.
- Affiliations
- Fondazione G.B. Bietti (IT)
- Istituto Superiore di Sanità (IT)
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
- Corresponding author
- Ziccardi, Lucia
- Cordeddu, Viviana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-14
- Volume
- 20
- Issue
- 22
- Pages
- 5722
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888000
- OpenAlex
- W2987842697
- Cited by
- 107
- References
- 188
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 11 · 2023: 13 · 2022: 16 · 2021: 25 · 2020: 18 · 2019: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- Funders
- Ministero della Salute
- Fondazione Roma
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, inherited retinal disease, Leber congenital amaurosis, Luxturna, disease-associated genes, molecular diagnosis, genome sequencing, clinical trials, translational research, retinal degeneration
- MeSH terms
- Gene Editing, Animals, Disease Models, Animal, Genetic Vectors, Humans, Genetic Therapy, Treatment Outcome, Gene Transfer Techniques, Transgenes, Genetic Predisposition to Disease, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.